Feature | April 07, 2011

New Study Results Show PPI Effects on Clopidogrel

April 7, 2011 – New study results have evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on clopidogrel (Plavix). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of dexlansoprazole (Dexilant) or lansoprazole, rather than esomeprazole.

The randomized, open-label, two-period, crossover study was designed to assess the effects of selected PPIs, a class of drugs used to treat gastroesophageal reflux disease, on the pharmacokinetics (PK) and pharmacodynamics (PD) of clopidogrel. Clopidogrel is a platelet-inhibiting drug that is indicated for the reduction of atherothrombotic events in patients with acute coronary syndromes, recent myocardial infarction, recent stroke or established peripheral arterial disease. The results were presented at the American College of Cardiology (ACC) 2011 60th Annual Scientific Session in New Orleans.

Studies have shown that PPIs may inhibit a liver enzyme (CYP2C19) important for the metabolism of clopidogrel. With CYP2C19 inhibition, clopidogrel may have reduced antiplatelet effects, potentially reducing its effectiveness. Because PPIs differ in their degree of inhibition of CYP2C19, using omeprazole as a positive control, this study evaluated the effect of several PPIs (dexlansoprazole, lansoprazole and esomeprazole) on the steady-state PK and PD of clopidogrel in healthy subjects.

"We conducted this study to look at the effect of select PPIs on Plavix and add to the growing body of evidence on the potential interaction between these drugs," said lead investigator Alan D. Michelson, M.D., professor of pediatrics at Harvard Medical School and director of the center for platelet research studies at Children's Hospital Boston. "We found that in healthy subjects the co-administration of Plavix with dexlansoprazole or lansoprazole reduced the antiplatelet effect of Plavix less than the co-administration of Plavix with esomeprazole."

The study showed that, while all PPIs decreased clopidogrel active metabolite peak plasma concentration, the area under the curve (AUC) decreased with treatment with esomeprazole, but not with dexlansoprazole or lansoprazole. The effect of PPI co-administration on clopidogrel's ability to inhibit platelet function varied among PPIs, with significant reductions in platelet reactivity index (PRI) for esomeprazole, but not for dexlansoprazole or lansoprazole. Esomeprazole reduced maximal platelet aggregation (MPA) and platelet response unit (PRU) more than dexlansoprazole or lansoprazole.

"Because there are many patients taking both a PPI and Plavix, it is important to gain a better understanding of how these medications interact with each other," said Gilles Delecoeuillerie, M.D., executive medical director, medical and scientific affairs, gastroenterology and internal medicine, Takeda. "This was the first prospective randomized study to comparatively assess the effects of certain PPIs, including dexlansoprazole, on the pharmacokinetic and pharmacodynamic characteristics of clopidogrel. Its results offer health care providers further information regarding the potential interaction between clopidogrel and several PPIs."

For more information: www.dexilant.com, www.tpna.com

Related Content

radiation dose in the cath lab
News | Radiation Dose Management| May 02, 2016
May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May
microtubules, heartbeat mechanics, Perelman School of Medicine study

Microtubules in a cardiomyocyte at rest (top) and when compressed. Image courtesy of the lab of Ben Prosser, Ph.D., Perelman School of Medicine, University of Pennsylvania

News | EP Lab| April 29, 2016
Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact...
breast cancer, herceptin chemotherapy drug, heart damage, monitoring, Journal of Clinical Oncology study
News | Cardiac Diagnostics| April 28, 2016
April 28, 2016 — Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored
coronary CT angiography, CCTA, SCOT-HEART trial substudy, SCCT
News | Computed Tomography (CT)| April 26, 2016
The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA)...
sleep patterns, metabolic syndrome, risk factors, ACC study
News | Cardiac Diagnostics| April 26, 2016
Taking long naps or being excessively tired during the day is associated with a higher risk for developing metabolic...
CABG, bypass surgery, heart failure, NHLBI study
News | Cardiovascular Surgery| April 25, 2016
Scientists have found that a greater number of patients with coronary artery disease may benefit from coronary artery...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
statins, heart disease, HOPE-3 trial, intermediate-risk patients, hypertension, ACC.16
News | Pharmaceuticals| April 20, 2016
Lowering cholesterol with statins significantly reduced adverse cardiovascular events in people with average...
Stepathlon, exercise, cardiovascular health, Anand Ganesan, ACC.16
News | Patient Engagement| April 20, 2016
April 20, 2016 — A competition that used technology to encourage and track physical activity was effective at...
post-operative atrial fibrillation, AFib, heart rate, rhythm control, ACC.16
News | Atrial Fibrillation| April 20, 2016
In the first large randomized trial to directly compare two approaches to preventing atrial fibrillation following...
Overlay Init